SANTA CLARA, Calif., April 06, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely ...
SANTA CLARA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of ...
SANTA CLARA, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified ...
Shockwave Medical, which markets a system that delivers ultrasound shockwaves to treat peripheral artery disease, has notched a CE mark, this time for the treatment of coronary artery disease. The ...
Shockwave Medical also announced enrollment of the first patient in EMPOWER CAD, the first prospective, all-female study of percutaneous coronary intervention, seeking to confirm the benefits of ...
SANTA CLARA, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely ...
Johnson & Johnson has put forward a clinical study exploring the use of its Shockwave Medical division’s vessel-clearing approach as the primary procedure for women with hardened, calcified blockages ...
Santa Clara, Calif.-based Shockwave Medical Inc. is working to build its business around the use of intravascular lithotripsy (IVL) in multiple arterial indications. Lithotripsy has been used to ...
SANTA CLARA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of ...
Next-generation intravascular lithotripsy (IVL) catheter resets physicians' expectations by addressing unmet needs in deliverability, lesion crossing and balloon repositioning Shockwave C2 ...
Shockwave Medical's Intravascular Lithotripsy (IVL) system has received premarket approval from the US Food and Drug Administration (FDA) to treat severely calcified coronary artery disease, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results